<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2381">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04511429</url>
  </required_header>
  <id_info>
    <org_study_id>062-2020</org_study_id>
    <nct_id>NCT04511429</nct_id>
  </id_info>
  <brief_title>COVID-19 in Immunosuppressed Children</brief_title>
  <official_title>COVID-19 in Immunosuppressed Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>D'Or Institute for Research and Education</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Estadual da Crian√ßa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Federal de Bonsucesso</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rio de Janeiro State Research Supporting Foundation (FAPERJ)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>D'Or Institute for Research and Education</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Viral respiratory infections are common infectious complications after kidney
      transplantation, especially in the pediatric age group, and immunosuppressed patients may
      develop more severe disease. Immunosuppressive medications alter the patient's immune
      response by acting on humoral, cellular immunity and neutrophil function, increasing the risk
      of serious viral infections. Little is known about how these patients respond to infection by
      the new coronavirus (SARS-CoV-2).

      Experience with SARS caused by the Influenza H1N1 virus suggests that the severity of the
      disease depends on pre-existing comorbidities and the individual immune response. In more
      severe cases, an imbalance between the inflammatory system and the immune system is observed,
      determining direct consequences when pro and anti-inflammatory cytokines reach the systemic
      circulation in an exacerbated and unbalanced manner. Such fact can generate &quot;cytokine storm
      syndrome&quot;, resulting in multiple organ dysfunction syndrome.

      March 2020 reports from Papa Giovanni XXIII Hospital in Bergamo, Italy - one of the largest
      pediatric liver transplant centers - showed that the number of transplant patients infected
      with Coronavirus disease 2019 (COVID- 19) increased progressively. However, they did not see
      greater severity and complications in this population. Immunosuppression could act as a
      protective factor.

      The present study aims to describe the prevalence of viral infection by SARS-CoV-2 in a
      sample of immunosuppressed children, from three groups: kidney transplants, liver transplants
      and oncohematological. The investigators will also look for the epidemiological profile and
      clinical evolution of these patients, enabling a better understanding of the COVID-19 in this
      special population. The investigators' hypothesis is that infection with the new coronavirus
      may be asymptomatic in a large number of children and that immunosuppression, observed in
      liver and kidney transplant patients and also seen in cancer patients, may act as protection
      for severe forms of COVID-19.

      After obtaining written informed consent from the family, the investigators will include
      patients from 0-18 years of age, on regular outpatient follow-up, symptomatic or not, and
      will check for the presence of IgM/IgG antibodies against the SARS-CoV-2. For those
      symptomatic or with a positive IgM result, material (oro/nasopharyngeal swabs) for RT-PCR
      trial for the new coronavirus will be collected. Demographic and clinical variables will be
      registered. The outcomes are: Serology for COVID-19 result; PCR for COVID-19 result; presence
      of symptoms of COVID-19; proportion of patients with viral shedding on days 3,7,14,21 and 30
      after diagnosis; need for hospital admission; need for Intensive care admission; death.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Variables to be measured

        -  Demographic data (initials, record, age, sex, race / ethnicity, weight, height, BMI).

        -  Epidemiological data:

             -  For kidney transplant patients: time of transplant, in years and complete months;
                primary kidney disease; presence and time of onset of respiratory symptoms, in
                days; presence of risk factors or comorbidities; current immunosuppression (drugs
                and doses); serum level of calcineurin inhibitor on the day of collection; previous
                vaccination for Influenza; previous viral infections; date of the last episode of
                rejection treated.

             -  For liver transplant patients: time of transplant, in years and complete months;
                primary liver disease; presence and time of onset of respiratory symptoms, in days;
                presence of risk factors or comorbidities; current immunosuppression (drugs and
                doses); serum level of calcineurin inhibitor on the day of collection; previous
                vaccination for Influenza; previous viral infections; date of the last episode of
                rejection treated.

             -  For oncohematological patients: time of diagnosis, in years and complete months;
                primary oncohematological disease; treatment received for the oncohematological
                disease; presence and time of onset of respiratory symptoms, in days; presence of
                risk factors or comorbidities; current cancer treatment; previous vaccination for
                Influenza; previous viral infections.

        -  Clinics visit / hospitalization data: clinical picture: syndromic diagnosis / signs and
           symptoms; initial image exam: chest X-ray and / or chest CT; Treatment performed:
           antiviral, antibiotic, corticoid (reason / dose / time); respiratory support (oxygen
           therapy only / Non-Invasive Ventilation / High Flow Nasal Cannula / invasive mechanical
           pulmonary ventilation / ECMO - time of use (days); days free of oxygen therapy,
           Non-Invasive Ventilation and invasive mechanical pulmonary ventilation.

        -  Diagnosis of SARS-CoV-2 infection: rapid test for Covid-19 in the blood: IgM / IgG;
           rapid test for COVID-19 in nasopharyngeal or tracheal secretion.

        -  Outcomes: Serology for COVID-19 result; PCR for COVID-19 result; presence of symptoms of
           COVID-19; proportion of patients with viral shedding on days 3,7,14,21 and 30 after
           diagnosis; need for hospital admission; need for Intensive care admission; death.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 30, 2020</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>6 Months</target_duration>
  <primary_outcome>
    <measure>Serology (IgM, IgG) for COVID-19.</measure>
    <time_frame>9 months</time_frame>
    <description>percentage of positivity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hospital admission</measure>
    <time_frame>9 months</time_frame>
    <description>percentage of patients admitted to hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensive care admission</measure>
    <time_frame>9 months</time_frame>
    <description>percentage of patients admitted to intensive care unit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>9 months</time_frame>
    <description>percentage of patients who died</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive PCR for COVID-19</measure>
    <time_frame>9 months</time_frame>
    <description>percentage of positivity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical characteristics of patients with COVID-19</measure>
    <time_frame>9 months</time_frame>
    <description>Percentage of patients with symptoms of COVID-19</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with viral excretion in respiratory secretion and faeces on days 3, 7, 14, 21 and 30 after confirmation of covid 19.</measure>
    <time_frame>9 months</time_frame>
    <description>Percentage of patients with positive PCR in respiratory secretion and feces on days 3, 7, 14, 21 and 30 after confirmation of covid 19.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Infections, Coronavirus</condition>
  <condition>Kidney Transplantation</condition>
  <condition>Liver Transplantation</condition>
  <condition>Cancer</condition>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Kidney transplant patients</arm_group_label>
    <description>Patients submitted to kidney transplantation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Liver transplant patients</arm_group_label>
    <description>Patients submitted to liver transplantation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oncological patients</arm_group_label>
    <description>Oncological patients submitted to chemotherapy.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients aged 0-18 years, immunosuppressed, kidney or liver transplanted, or oncologic
        patients, in outpatient follow-up or hospitalized.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Renal or liver transplant patients, with functioning graft and using
             immunosuppression, in outpatient follow-up or hospitalized.

          -  Patients treating oncohematological disorders, in outpatient follow-up or
             hospitalized..

        Exclusion Criteria:

          -  Patients who or whose parents refuse to sign the Informed Consent Form.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thais L Cleto-Yamane, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>D'Or Institute for Research and Education (IDOR)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Arnaldo Prata-Barbosa, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>D'Or Institute for Research and Education (IDOR)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antonio Jos√© L A da Cunha, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Universidade Federal do Rio de Janeiro</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thais L Cleto-Yamane, MD, MSc</last_name>
    <phone>5521988046852</phone>
    <email>thaiscleto@yahoo.com.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Arnaldo Prata-Barbosa, MD, PhD</last_name>
    <phone>5521999744098</phone>
    <email>arnaldoprata@globo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Federal de Bonsucesso</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <zip>21041030</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaqueline LS Gouveia, MD</last_name>
      <phone>5521981737514</phone>
      <email>jaqueleal@yahoo.com.br</email>
    </contact>
    <investigator>
      <last_name>Jaqueline LS Gouveia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Estadual da Crian√ßa</name>
      <address>
        <city>Rio De Janeiro</city>
        <state>RJ</state>
        <zip>21321230</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thais L Cleto-Yamane</last_name>
      <phone>5521988046852</phone>
      <email>thaiscleto@yahoo.com.br</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <results_reference>
    <citation>Danziger-Isakov L, Steinbach WJ, Paulsen G, Munoz FM, Sweet LR, Green M, Michaels MG, Englund JA, Murray A, Halasa N, Dulek DE, Madan RP, Herold BC, Fisher BT. A Multicenter Consortium to Define the Epidemiology and Outcomes of Pediatric Solid Organ Transplant Recipients With Inpatient Respiratory Virus Infection. J Pediatric Infect Dis Soc. 2019 Jul 1;8(3):197-204. doi: 10.1093/jpids/piy024.</citation>
    <PMID>29538674</PMID>
  </results_reference>
  <results_reference>
    <citation>Lee KH, Yoo SG, Cho Y, Kwon DE, La Y, Han SH, Kim MS, Choi JS, Kim SI, Kim YS, Min YH, Cheong JW, Kim JS, Song YG. Characteristics of community-acquired respiratory viruses infections except seasonal influenza in transplant recipients and non-transplant critically ill patients. J Microbiol Immunol Infect. 2019 Jun 19. pii: S1684-1182(18)30233-0. doi: 10.1016/j.jmii.2019.05.007. [Epub ahead of print]</citation>
    <PMID>31262511</PMID>
  </results_reference>
  <results_reference>
    <citation>D'Antiga L. Coronaviruses and Immunosuppressed Patients: The Facts During the Third Epidemic. Liver Transpl. 2020 Jun;26(6):832-834. doi: 10.1002/lt.25756. Epub 2020 Apr 24.</citation>
    <PMID>32196933</PMID>
  </results_reference>
  <results_reference>
    <citation>Cortiula F, Pettke A, Bartoletti M, Puglisi F, Helleday T. Managing COVID-19 in the oncology clinic and avoiding the distraction effect. Ann Oncol. 2020 May;31(5):553-555. doi: 10.1016/j.annonc.2020.03.286. Epub 2020 Mar 19.</citation>
    <PMID>32201224</PMID>
  </results_reference>
  <results_reference>
    <citation>Ronco C, Reis T, De Rosa S. Coronavirus Epidemic and Extracorporeal Therapies in Intensive Care: si vis pacem para bellum. Blood Purif. 2020;49(3):255-258. doi: 10.1159/000507039. Epub 2020 Mar 13.</citation>
    <PMID>32172242</PMID>
  </results_reference>
  <results_reference>
    <citation>Memoli MJ, Athota R, Reed S, Czajkowski L, Bristol T, Proudfoot K, Hagey R, Voell J, Fiorentino C, Ademposi A, Shoham S, Taubenberger JK. The natural history of influenza infection in the severely immunocompromised vs nonimmunocompromised hosts. Clin Infect Dis. 2014 Jan;58(2):214-24. doi: 10.1093/cid/cit725. Epub 2013 Nov 1.</citation>
    <PMID>24186906</PMID>
  </results_reference>
  <results_reference>
    <citation>Fitzner J, Qasmieh S, Mounts AW, Alexander B, Besselaar T, Briand S, Brown C, Clark S, Dueger E, Gross D, Hauge S, Hirve S, Jorgensen P, Katz MA, Mafi A, Malik M, McCarron M, Meerhoff T, Mori Y, Mott J, Olivera MTDC, Ortiz JR, Palekar R, Rebelo-de-Andrade H, Soetens L, Yahaya AA, Zhang W, Vandemaele K. Revision of clinical case definitions: influenza-like illness and severe acute respiratory infection. Bull World Health Organ. 2018 Feb 1;96(2):122-128. doi: 10.2471/BLT.17.194514. Epub 2017 Nov 27.</citation>
    <PMID>29403115</PMID>
  </results_reference>
  <results_reference>
    <citation>Kumar D, Tellier R, Draker R, Levy G, Humar A. Severe Acute Respiratory Syndrome (SARS) in a liver transplant recipient and guidelines for donor SARS screening. Am J Transplant. 2003 Aug;3(8):977-81.</citation>
    <PMID>12859532</PMID>
  </results_reference>
  <results_reference>
    <citation>Liang W, Guan W, Chen R, Wang W, Li J, Xu K, Li C, Ai Q, Lu W, Liang H, Li S, He J. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020 Mar;21(3):335-337. doi: 10.1016/S1470-2045(20)30096-6. Epub 2020 Feb 14.</citation>
    <PMID>32066541</PMID>
  </results_reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>July 24, 2020</study_first_submitted>
  <study_first_submitted_qc>August 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 13, 2020</study_first_posted>
  <last_update_submitted>August 12, 2020</last_update_submitted>
  <last_update_submitted_qc>August 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Kidney transplantation</keyword>
  <keyword>Liver transplantation</keyword>
  <keyword>Cancer</keyword>
  <keyword>Children</keyword>
  <keyword>Adolescents</keyword>
  <keyword>Pediatrics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 1, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/29/NCT04511429/ICF_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 1, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/29/NCT04511429/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

